TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26

作者：

Ahn, M. ^{[1
]}

Han, J. ^{[2
]}

Sequist, L. ^{[3
]}

Cho, B. C. ^{[4
]}

Lee, J. S. ^{[5
]}

Kim, S. ^{[6
]}

Su, W. ^{[7
]}

Tsai, C. ^{[8
]}

Yang, J. C. ^{[9
]}

Yu, H. ^{[10
]}

Horn, L. ^{[11
]}

Lee, K. ^{[12
]}

Haddad, V. ^{[13
]}

Frigault, M. ^{[14
]}

Ahmed, G. ^{[13
]}

Yang, L. ^{[15
]}

Ghiorghiu, D. ^{[13
]}

Oxnard, G. ^{[16
]}

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan

[13] Astrazeneca, Cambridge, England

[14] Astrazeneca, Waltham, MA USA

[15] Astrazeneca, Shanghai, Peoples R China

[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

non-small cell lung cancer; EGFR-Mutant; MET-amplification;

D O I：

10.1016/j.jtho.2017.09.377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 09.03

引用

页码：S1768 / S1768

页数：1